{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:58:33Z","timestamp":1790524713258,"version":"4.1.0"},"reference-count":39,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Data on diuretic treatment in nephrotic syndrome (NS) are scarce. Our goal was to assess the non-inferiority of the combined oral diuretics (furosemide\/hydrochlorothiazide\/amiloride) compared to intravenous (i.v.) furosemide in patients with NS and resistant edema. Methods: We conducted a prospective randomized trial on 22 patients with resistant nephrotic edema (RNE), defined as hypervolemia and a FENa &lt; 0.2%. Based on a computer-generated 1:1 randomization, we assigned patients to receive either intravenous furosemide (40 mg bolus and then continuous administration of 5 mg\/h) or oral furosemide (40 mg\/day) and hydrochlorothiazide\/amiloride (50\/5 mg\/day) for a period of 5 days. Clinical and laboratory measurements were performed daily. Hydration status was assessed by bioimpedance on day 1 and at the end of day 5 after treatment initiation. The primary endpoint was weight change from baseline to day 5. Secondary endpoints were hydration status change measured by bioimpedance and safety outcomes (low blood pressure, severe electrolyte disturbances, acute kidney injury and worsening hypervolemia). Results: Primary endpoint analysis showed that after 5 days of treatment, there was a significant difference in weight change from baseline between groups [adjusted mean difference: \u22123.33 kg (95% CI: \u22126.34 to \u22120.31), p = 0.03], with a higher mean weight change in the oral diuretic treatment group [\u22127.10 kg (95% CI: \u221218.30 to \u22124.30) vs. \u22124.55 kg (95%CI: \u22126.73 to \u22122.36)]. Secondary endpoint analysis showed that there was no significant difference between groups regarding hydration status change [adjusted mean difference: \u22120.05 L (95% CI: \u22122.6 to 2.6), p = 0.96], with a mean hydration status change in the oral diuretic treatment group of \u22124.71 L (95% CI: \u22126.87 to \u22122.54) and \u22123.91 L (95% CI: \u22125.69 to \u22122.13) in the i.v. diuretic treatment group. We observed a significant decrease in adjusted mean serum sodium of \u22122.15 mmol\/L [(95% CI: \u22124.25 to \u22120.05), p = 0.04]), favored by the combined oral diuretic treatment [\u22122.70 mmol\/L (95% CI: \u22124.89 to \u22120.50) vs. \u22120.10 mmol\/L (95%CI: \u22121.30 to 1.10)]. No statistically significant difference was observed between the two groups in terms of adverse events. Conclusions: A combination of oral diuretics based on furosemide, amiloride and hydrochlorothiazide is non-inferior to i.v. furosemide in weight control of patients with RNE and a similar safety profile.<\/jats:p>","DOI":"10.3390\/jcm12216895","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T02:05:07Z","timestamp":1698890707000},"page":"6895","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Oral Furosemide and Hydrochlorothiazide\/Amiloride versus Intravenous Furosemide for the Treatment of Resistant Nephrotic Syndrome"],"prefix":"10.3390","volume":"12","author":[{"given":"Georgiana","family":"Fr\u0103\u021bil\u0103","sequence":"first","affiliation":[{"name":"Department of Nephrology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3574-4635","authenticated-orcid":false,"given":"Bogdan","family":"Sorohan","sequence":"additional","affiliation":[{"name":"Department of Nephrology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Kidney Transplantation, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camelia","family":"Achim","sequence":"additional","affiliation":[{"name":"Department of Nephrology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5590-7879","authenticated-orcid":false,"given":"Andreea","family":"Andronesi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Obri\u0219c\u0103","sequence":"additional","affiliation":[{"name":"Department of Nephrology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5274-6862","authenticated-orcid":false,"given":"Gabriela","family":"Lupu\u0219oru","sequence":"additional","affiliation":[{"name":"Department of Nephrology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Zili\u0219teanu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Jurubi\u021b\u0103","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca","family":"Bobeic\u0103","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"B\u0103l\u0103nic\u0103","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Micu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Mocanu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gener","family":"Ismail","sequence":"additional","affiliation":[{"name":"Department of Nephrology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.3389\/fphys.2018.01868","article-title":"Nephrotic Syndrome: Oedema Formation and Its Treatment with Diuretics","volume":"9","author":"Gupta","year":"2018","journal-title":"Front. Physiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"975934","DOI":"10.1155\/2015\/975934","article-title":"Clinical Use of Diuretics in Heart Failure, Cirrhosis, and Nephrotic Syndrome","volume":"2015","author":"Qavi","year":"2015","journal-title":"Int. J. Nephrol."},{"key":"ref_3","first-page":"111","article-title":"Pathophysiology, Evaluation, and Management of Edema in Childhood Nephrotic Syndrome","volume":"3","author":"Ellis","year":"2015","journal-title":"Front. Pediatr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/ki.1994.33","article-title":"Mechanisms and Management of Nephrotic Edema","volume":"45","author":"Humphreys","year":"1994","journal-title":"Kidney Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s12098-020-03252-9","article-title":"Current Perspectives in Management of Edema in Nephrotic Syndrome","volume":"87","author":"Meena","year":"2020","journal-title":"Indian J. Pediatr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"688","DOI":"10.7326\/0003-4819-91-5-688","article-title":"Nephrotic Syndrome: Vasoconstriction and Hypervolemic Types Indicated by Renin-Sodium Profiling","volume":"91","author":"Meltzer","year":"1979","journal-title":"Ann. Intern. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/01.ASN.0000013292.78621.FD","article-title":"Angiotensin II Directly Stimulates ENaC Activity in the Cortical Collecting Duct via AT(1) Receptors","volume":"13","author":"Warnock","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000183206","article-title":"Lack of Effect of Captopril on the Sodium Retention of the Nephrotic Syndrome","volume":"37","author":"Brown","year":"1984","journal-title":"Nephron"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1681\/ASN.V123598","article-title":"Collecting Duct Is a Site of Sodium Retention in PAN Nephrosis: A Rationale for Amiloride Therapy","volume":"12","author":"Wittner","year":"2001","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_10","first-page":"23","article-title":"Controlled clinical study on 2 antialdosterone diuretics in the nephrotic syndrome","volume":"109","author":"Russo","year":"1984","journal-title":"Clin. Ter."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000168052","article-title":"Role of Aldosterone in the Sodium Retention of Patients with Nephrotic Syndrome","volume":"10","author":"Shapiro","year":"1990","journal-title":"Am. J. Nephrol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000013347","article-title":"Hyporeninemic Hypoaldosteronism in Patients with Nephrotic Syndrome","volume":"18","author":"Usberti","year":"1998","journal-title":"Am. J. Nephrol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1172\/JCI110756","article-title":"Role for Intrarenal Mechanisms in the Impaired Salt Excretion of Experimental Nephrotic Syndrome","volume":"71","author":"Ichikawa","year":"1983","journal-title":"J. Clin. Investig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1681\/ASN.2005040363","article-title":"Hyperaldosteronemia and Activation of the Epithelial Sodium Channel Are Not Required for Sodium Retention in Puromycin-Induced Nephrosis","volume":"16","author":"Lourdel","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"F208","DOI":"10.1152\/ajprenal.00399.2005","article-title":"Increased Expression but Not Targeting of ENaC in Adrenalectomized Rats with PAN-Induced Nephrotic Syndrome","volume":"291","author":"Kim","year":"2006","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"F429","DOI":"10.1152\/ajprenal.00237.2015","article-title":"Amiloride: The \u201cNew\u201d Renal Tonic?","volume":"309","author":"Warnock","year":"2015","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1056\/NEJMra1703100","article-title":"Diuretic Treatment in Heart Failure","volume":"377","author":"Ellison","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Solis-Jimenez, F., Perez-Navarro, L.M., Cabrera-Barron, R., Chida-Romero, J.A., Martin-Alema\u00f1y, G., Dehesa-L\u00f3pez, E., Madero, M., and Valdez-Ortiz, R. (2022). Effect of the Combination of Bumetanide plus Chlorthalidone on Hypertension and Volume Overload in Patients with Chronic Kidney Disease Stage 4-5 KDIGO without Renal Replacement Therapy: A Double-Blind Randomized HEBE-CKD Trial. BMC Nephrol., 23.","DOI":"10.1186\/s12882-022-02930-4"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2010.06.034","article-title":"Combination of Loop Diuretics with Thiazide-Type Diuretics in Heart Failure","volume":"56","author":"Jentzer","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/ejhf.1478","article-title":"Acetazolamide to Increase Natriuresis in Congestive Heart Failure at High Risk for Diuretic Resistance","volume":"21","author":"Verbrugge","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s40261-017-0577-1","article-title":"Acetazolamide as Add-on Diuretic Therapy in Exacerbations of Chronic Heart Failure: A Pilot Study","volume":"37","author":"Imiela","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO Clinical Practice Guidelines for Acute Kidney Injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron. Clin. Pract."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1440-1681.1975.tb01834.x","article-title":"Potassium-Sparing Effect of Amiloride in a Diuretic Factorial Study in Man","volume":"2","author":"Schapel","year":"1975","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.ajkd.2016.10.022","article-title":"Acetazolamide and Hydrochlorothiazide Followed by Furosemide versus Furosemide and Hydrochlorothiazide Followed by Furosemide for the Treatment of Adults with Nephrotic Edema: A Randomized Trial","volume":"69","author":"Fallahzadeh","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00467-013-2435-6","article-title":"Over- or Underfill: Not All Nephrotic States Are Created Equal","volume":"28","author":"Bockenhauer","year":"2013","journal-title":"Pediatr. Nephrol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s00467-007-0521-3","article-title":"Molecular Mechanism of Edema Formation in Nephrotic Syndrome: Therapeutic Implications","volume":"22","author":"Doucet","year":"2007","journal-title":"Pediatr. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/ndt\/gfu402","article-title":"Diabetic Nephropathy Is Associated with Increased Urine Excretion of Proteases Plasmin, Prostasin and Urokinase and Activation of Amiloride-Sensitive Current in Collecting Duct Cells","volume":"30","author":"Andersen","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1161\/HYPERTENSIONAHA.112.198879","article-title":"Urinary Plasmin Activates Collecting Duct ENaC Current in Preeclampsia","volume":"60","author":"Buhl","year":"2012","journal-title":"Hypertension"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1097\/HJH.0000000000000216","article-title":"Plasmin in Urine from Patients with Type 2 Diabetes and Treatment-Resistant Hypertension Activates ENaC in vitro","volume":"32","author":"Buhl","year":"2014","journal-title":"J. Hypertens."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1161\/HYPERTENSIONAHA.115.05838","article-title":"Urinary Proteolytic Activation of Renal Epithelial Na+ Channels in Chronic Heart Failure","volume":"67","author":"Zheng","year":"2016","journal-title":"Hypertension"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2215\/CJN.12261115","article-title":"Association of Plasminuria with Overhydration in Patients with CKD","volume":"11","author":"Schork","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ekir.2017.05.008","article-title":"Trial of Amiloride in Type 2 Diabetes with Proteinuria","volume":"2","author":"Unruh","year":"2017","journal-title":"Kidney Int. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1097\/HJH.0000000000000967","article-title":"Significant Natriuretic and Antihypertensive Action of the Epithelial Sodium Channel Blocker Amiloride in Diabetic Patients with and without Nephropathy","volume":"34","author":"Andersen","year":"2016","journal-title":"J. Hypertens."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e13743","DOI":"10.14814\/phy2.13743","article-title":"Amiloride Resolves Resistant Edema and Hypertension in a Patient with Nephrotic Syndrome; a Case Report","volume":"6","author":"Hinrichs","year":"2018","journal-title":"Physiol. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1053\/j.ajkd.2016.08.027","article-title":"Diuretic Resistance","volume":"69","author":"Hoorn","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e13835","DOI":"10.14814\/phy2.13835","article-title":"ENaC Blockade in Proteinuria-Associated Extracellular Fluid Volume Overload\u2014Effective but Risky","volume":"6","author":"Ray","year":"2018","journal-title":"Physiol. Rep."},{"key":"ref_37","first-page":"CD011339","article-title":"Diuretics for People with Chronic Kidney Disease","volume":"2017","author":"Shah","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.2215\/CJN.09630818","article-title":"Clinical Pharmacology in Diuretic Use","volume":"14","author":"Ellison","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2012-03-413682","article-title":"How I Treat Amyloidosis: The Importance of Accurate Diagnosis and Amyloid Typing","volume":"120","author":"Leung","year":"2012","journal-title":"Blood"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/21\/6895\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:15:47Z","timestamp":1760130947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/21\/6895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":39,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["jcm12216895"],"URL":"https:\/\/doi.org\/10.3390\/jcm12216895","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}